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Essentials
• Glycoprotein VI (GPVI) binds collagen, starting throm-
bogenesis, and fibrin, stabilizing thrombi.
• GPVI-dimers, not monomers, recognize immobilized
fibrinogen and fibrin through their D-domains.
• Collagen, D-fragment and D-dimer may share a com-
mon or proximate binding site(s) on GPVI-dimer.
• GPVI-dimer–fibrin interaction supports spreading, acti-
vation and adhesion involving aIIbb3.
Summary. Background: Platelet collagen receptor Glyco-
protein VI (GPVI) binds collagen, initiating thrombogen-
esis, and stabilizes thrombi by binding fibrin. Objectives:
To determine if GPVI-dimer, GPVI-monomer, or both
bind to fibrinogen substrates, and which region common
to these substrates contains the interaction site. Meth-
ods: Recombinant GPVI monomeric extracellular domain
(GPVIex) or dimeric Fc-fusion protein (GPVI-Fc2) bind-
ing to immobilized fibrinogen derivatives was measured
by ELISA, including competition assays involving col-
lagenous substrates and fibrinogen derivatives. Flow
adhesion was performed with normal or Glanzmann
thrombasthenic (GT) platelets over immobilized fibrino-
gen, with or without anti-GPVI-dimer or anti-aIIbb3. Re-
sults: Under static conditions, GPVIex did not bind to
any fibrinogen substrate. GPVI-Fc2 exhibited specific, sat-
urable binding to both D-fragment and D-dimer, which
was inhibited by mFab-F (anti-GPVI-dimer), but showed
low binding to fibrinogen and fibrin under our conditions.
GPVI-Fc2 binding to D-fragment or D-dimer was abro-
gated by collagen type III, Horm collagen or CRP-XL
(crosslinked collagen-related peptide), suggesting proxim-
ity between the D-domain and collagen binding sites on
GPVI-dimer. Under low shear, adhesion of normal plate-
lets to D-fragment, D-dimer, fibrinogen and fibrin was
inhibited by mFab-F (inhibitor of GPVI-dimer) and abol-
ished by Eptifibatide (inhibitor of aIIbb3), suggesting that
both receptors contribute to thrombus formation on these
substrates, but aIIbb3 makes a greater contribution.
Notably, thrombasthenic platelets showed limited adhe-
sion to fibrinogen substrates under flow, which was fur-
ther reduced by mFab-F, supporting some independent
GPVI-dimer involvement in this interaction. Conclusion:
Only dimeric GPVI interacts with fibrinogen D-domain,
at a site proximate to its collagen binding site, to support
platelet adhesion/activation/aggregate formation on
immobilized fibrinogen and polymerized fibrin.
Keywords: fibrin; fibrin fragment D-dimer; fibrinogen
fragment D; platelet membrane glycoprotein VI; platelet
membrane glycoproteins; receptors, collagen.
Introduction
Myocardial infarction and ischemic stroke, leading causes
of disability and death worldwide [1], usually result from
atherosclerotic plaque rupture, leading to arterial throm-
bus formation followed by distal tissue infarction; plate-
lets are crucial for the development of such thrombi.
Disruption of the thrombo-protective endothelial layer
within blood vessels during plaque rupture exposes colla-
gen and tissue factor (TF). Platelet GPIb-IX-V binds to
von Willebrand factor (VWF) deposited on exposed
subendothelial collagens, slowing them down so
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Glycoprotein VI (GPVI) can bind to the collagen, which
initiates a signaling cascade leading to thrombus forma-
tion [2,3]. A dimer consisting of two GPVI-monomers is
the functionally active form of this receptor, which is con-
stitutively present (about 20% of the total GPVI) on rest-
ing platelets [4]. GPVI-dimers recognize Gly-Pro-Hyp
(GPO) peptide repeats on collagen [5,6] and once platelets
adhere via GPVI, activation of integrin a2b1 supports
firm adhesion to collagen [7].
The subsequent growth and stability of a clot relies on
coordinated activation of both the collagen pathway and
TF (tissue factor) pathway [8], which can also form
thrombi independent of collagen exposure [9], relying on
thrombin (factor IIa) generation via the proteolytic
extrinsic coagulation cascade. Thrombin generates insol-
uble fibrin from soluble circulating fibrinogen, which
polymerizes and acts to stabilize the growing clot via pla-
telet receptor integrin aIIbb3 [10,11].
Human fibrinogen molecules are comprised of six disul-
fide-linked polypeptide chains (Aa, Bb, c)2 organized as
outer D-domains containing the C-termini of the three
chains, connected to a central E-domain. Thrombin cleaves
fibrinopeptides A and B from the N-termini of the a- and
b-chains within the E-domain, exposing new binding sites
that allow fibrin polymerization through linking to one or
two D-domains in an end-to-middle configuration [12]. D-
domain c-chains undergo reciprocal crosslinking mediated
by FXIIIa, leading to a strengthened fibrin mesh [13]. The
peptide Gly-Pro-Arg-Pro (GPRP), which binds to the fibrin
polymerization sites in the D-domain, inhibits its binding
to an adjacent E-domain, leading to formation of non-
crosslinked, or monomeric fibrin [14]. Plasmin can act on
fibrinogen to release D- or E-domains separately, or on
polymerized fibrin to release D-dimer, typically consisting
of two FXIIIa crosslinked D-domains from an original fib-
rinogen molecule [15].
Initially, aIIbb3 is converted to its high-affinity form,
enabling binding to fibrinogen and fibrin, leading to pla-
telet aggregation, thrombus growth and formation of a
hemostatic plug [16]. The complex role that aIIbb3 plays
in thrombus formation has already been extensively inves-
tigated, but translation of its inhibition to an antiplatelet
agent has not been successful in conditions such as
ischemic stroke [17].
It has been long suspected that GPVI plays a role in
thrombus growth independent of collagen exposure
through ligands such as thrombin [18,19], laminin [20],
fibronectin [21,22] and vitronectin [23]. Recently, it has
been reported that GPVI interacts with polymerized fibrin
to facilitate thrombus growth [24–26].
The present study provides evidence indicating that the
collagen-binding, dimeric form of GPVI, is also able to
recognize the D-domain, a region universal to fibrinogen,
D-fragment (resulting from proteolytic cleavage of fib-
rinogen), D-dimer, and monomeric and polymerized
fibrin. The binding site on GPVI-dimer for the D-domain
is proximate to its collagen-binding site and GPVI-dimer
assists aIIbb3 in thrombus growth and stabilization,
suggesting that GPVI-dimer could be the central platelet
receptor linking both collagen and TF pathways in
thrombosis.
Materials and methods
Fibrinogen/fibrinogen derivatives
Figure S1 summarizes the commercial preparations of
human fibrinogen and derivatives used; SDS-PAGE con-
firmed the manufacturer’s stated purity. Preliminary stud-
ies showed that all the listed fibrinogens gave similar
results. We used Fibrinogen 3 (Fbg-3) in this study
because it was plasminogen-, VWF- and fibronectin-
depleted, but not factor XIII– depleted.
Recombinant GPVI-dimer and -monomer
GPVIex is a recombinant protein comprising the extracel-
lular domain of GPVI, including the collagen binding
portions D1D2 and most of the highly glycosylated extra-
cellular stem portion. GPVI-Fc2 is a fusion protein of the
GPVI extracellular domain (same amino acid sequence as
GPVIex) and the Fc domain of IgG, which spontaneously
dimerizes ([GPVI-Fc]2, abbreviated as GPVI-Fc2). Both
proteins were designed and characterized by M. Moroi
and colleagues [4,27].
Collagen substrates (synthesized and crosslinked in-house)
CRP-XL (crosslinked collagen-related peptide; GCO-
(GPO)10-GCOG-NH2) is a GPVI-specific agonist [28] and
GPP10-XL is its inactive analogue (GCP-(GPP)10G-NH2) [5].
GPVI-dimer-specific antibodies
mFab-F is a GPVI-dimer-specific inhibitory Fab [3] that
recognizes the dimers on resting platelets. GPVI-dimer-
specific non-inhibitory 204-11 Fab [4] recognizes the
GPVI-dimers on resting and activated platelets. Both
antibodies were developed by M Moroi and colleagues.
Immobilization of fibrinogen substrates and collagens
For ELISA, static adhesion, confocal microscopy and flow
adhesion, respectively, 96-well black optical polymer-bot-
tom ELISA plates (Nunc A/S, Roskilde, Denmark), Max-
isorp ELISA plates (Nunc A/S), glass-bottomed dishes (10-
mm, No. 0; MatTek, Ashland, MA, USA) or glass slides
were incubated with fibrinogen or collagenous substrates in
phosphate-buffered saline (PBS; for all substrates except
Horm, which was diluted in supplied diluent), overnight at
4 °C; details are provided in the figure legends. The immo-
bilized surfaces were blocked by incubating with 1%
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bovine serum albumin (BSA)/PBS for 1 h, washed twice
with PBS, and used for experiments.
Polymerized fibrin (pFibrin) was prepared by adding
thrombin (2 U mL1; Sigma-Aldrich, Dorset, England)
to Fbg-3 (10 lg mL1 unless otherwise stated), and
incubated for 30 min at RT, aliquoted to the surface
to be coated and left overnight at 4 °C. The coated
surface was blocked with 1% BSA, treated with hiru-
din or protease inhibitor cocktail for 10 min to inhibit
active thrombin, and washed with PBS. The presence
of fibrin strands was confirmed by staining with anti-
fibrin (UC45)/Alexa-Fluor-Plus 555 anti-mouse IgG
(ThermoFisher Scientific, Warrington, UK); Fig. 4(B)
shows a representative image.
Immobilized monomeric fibrin (mFibrin) was prepared
by adding GPRP (2 mM) to Fbg-3 (10 lg mL1, unless
stated otherwise) and incubated for 30 min at RT before
adding thrombin as above; other procedures are the same
as for pFibrin.
ELISA analysis of GPVI-dimer and GPVI-monomer binding
to fibrinogen and its derivatives
GPVI binding to immobilized substrates was measured
by ELISA as described previously [4]. Bound GPVI
was measured by reacting the wells with 1G5 (mouse
anti-pan GPVI Mab; Biocytex, Marseille, France)
[20,29] followed by IRDye800CW goat anti-mouse
IgG (Licor Biosciences, Cambridge, UK) or Alexa-
fluor 647-conjugated anti-human Fc (BioLegend, Lon-
don, UK).
Washed platelets
ACD-anticoagulated blood from healthy volunteers or the
Glanzmann thrombasthenic (GT) patient was obtained
with informed consent, in accordance with the Treaty of
Helsinki. Washed platelets were prepared as described pre-
viously [30] and resuspended in HEPES-Tyrode’s buffer
(HT: 134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl,
12 mM NaHCO3, 10 mM N-2-hydroxyethylpiperazine-N’-
2-ethanesulfonic acid, 5.5 mM glucose, pH 7.3).
Other platelet assays
Aggregometry was performed with a PAP-8E aggre-
gometer (Bio/Data Corporation, Alpha Laboratories
(UK distributor), Hampshire, UK); details are given in
the legend for Fig. 5. Flow cytometry was performed
with an Accuri C6 flow cytometer (BD, Oxford, UK) on
washed platelets; details are given in the legend for
Fig. 3. Static platelet adhesion (Fig. 3) experiments were
performed as described previously [4] to determine the
effects of mFab-F and Hip8 (anti-aIIbb3) on adhesion
of washed platelets to fibrinogen-substrate-coated or col-
lagen-coated ELISA plates.
Confocal imaging
Washed platelets (3 9 107 mL1 in HT/2 mM MgCl2)
were allowed to adhere on fibrinogen-substrate-coated
MatTek dishes for 1 h at 37 °C and formalin fixed as
described previously [31]. Pre- and post-staining details
are provided in the figure legends. Stained samples were
imaged under an Olympus FV300 IX81 laser-scanning
confocal microscope (Olympus, Essex, UK), with a 60x
oil immersion objective).
Effect of anti-GPVI-dimer antibodies on platelets under flow
Flow adhesion experiments were performed with normal
or GT blood and image acquisition was carried out as
described [32]; details are given in the figure legends.
After 5 min, Z-stacks (DZ = 0.69-lm increments from the
coverslip plane) were collected and analyzed by Ima-
geJ1.35 (National Institutes of Health). The coverslip
plane was defined as the Z-plane with the largest fluores-
cent platelet area and used to calculate the surface area
coverage (SA; lm2). Thrombus volume (lm3) was calcu-
lated as the sum of the detected surface areas of all
images in the Z-stack, multiplied by DZ. Mean thrombus
height (MTH) was calculated as thrombus volume/field
area.
Data analyses
Non-linear regression (one-site model) to obtain dissocia-
tion constants (Kd) and statistical analyses was performed
with Prism version 7.2 (GraphPad Software, San Diego,
CA, USA).
Results
Dimeric, but not monomeric, GPVI binds to immobilized D-
fragment and D-dimer with high affinity
We measured GPVI-Fc2 binding to immobilized fibrinogen
derivatives and collagen III (col III) (Fig. 1A;
mean  SEM, 3 experiments, duplicate replicates). GPVI-
Fc2 showed high levels of binding to D-fragment and D-
dimer, but did not bind E-fragment. There was very low
but measurable binding to fibrinogen, pFibrin and mFib-
rin. GPVI-Fc2 binding to D-fragment or D-dimer was
specific and saturable, their Kd values being higher but sim-
ilar in magnitude to that for col III (Fig. 1E). At all coating
concentrations (10–200 lg mL1, Fig. 1C), fibrinogen,
mFibrin or pFibrin binding was too low and scattered to
determine Kd. Bmax, which depends on the amount of
immobilized substrate, cannot be determined by ELISA.
Monomeric GPVI, GPVIex (0–50 lg mL
1), did not
bind D-fragment, D-dimer or fibrinogen and exhibited
feeble col III binding compared with GPVI-Fc2, as previ-
ously reported [4] (Fig. 1B).
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Furthermore, mFab-F significantly reduces GPVI-Fc2
binding to D-fragment (P < 0.01), D-dimer (P < 0.01)
and collagen type III (P < 0.05), compared with a non-
specific human Fab (hFab; Jackson ImmunoResearch)
control (Fig. 5B). These results suggest that the binding
site for GPVI lies in the D-domain, universally present in
fibrinogen, D-dimer, mFibrin and pFibrin, for which only
GPVI-dimer has good affinity.
Human Fc and DDR2-Fc2 (recombinant Fc-fusion
protein of discoidin domain-containing receptor 2,
another collagen-binding protein [33]) and human IgG
did not bind to any of the fibrinogen substrates, whereas
DDR2-Fc2 bound to collagen as expected, confirming the
specificity of our assay to the GPVI portion of GPVI-Fc2
(Fig. 1D).
Collagenous substrates inhibit the binding of GPVI-dimer to
D-fragment and D-dimer, suggesting proximity of binding
sites
To determine if the binding site on GPVI-dimer for
D-fragment and D-dimer is close to that for collagen, we
incubated GPVI-Fc2 (20 lg mL
1) with 0–20 lg mL1 of
col III (non-fibrous), Horm collagen (fibrous), CRP-XL
and GPP10-XL and reacted it with immobilized D-frag-
ment and D-dimer. The converse experiment, where
immobilized collagenous substrates were reacted with
GPVI-Fc2 incubated with fibrinogen, fibrins or fibrinogen
subdomains, was also performed (described in next sec-
tion). Col III and Horm showed similar concentration-
dependent abilities to inhibit binding of GPVI-Fc2 to D-
fragment, with complete inhibition at ≥ 0.5 lg mL1
(Fig. 2A-i). CRP-XL was effective at lower concentra-
tions, producing complete inhibition at ≥ 0.05 lg mL1.
Higher col III and Horm concentrations were needed to
inhibit GPVI-Fc2 binding to D-dimer, whereas the inhibi-
tion curve of CRP-XL was similar to that against D-frag-
ment (Fig. 2A-ii). As expected, GPP10-XL had little
effect against GPVI-Fc2 binding.
Determining if GPVI-Fc2 and platelet GPVI can interact with
fibrinogen or its derivatives in solution
D-fragment, E-fragment, D-dimer, fibrinogen and pFibrin
(0–20 lg mL1) could not inhibit binding of GPVI-Fc2
(20 lg mL1) to immobilized col III, Horm or CRP-XL
(Fig. 2B i–iii), suggesting that GPVI-Fc2 cannot bind to
them in solution.
Flow cytometry (Fig. 5C) shows that the washed nor-
mal platelets bind to fibrinogen and D-dimer, at a low
level, but thrombasthenic platelets that lack aIIbb3 exhi-
bit no binding to either. This means that activation
through aIIbb3 is required for expression of D-dimer
and fibrinogen binding; in this case, the platelets may
have become slightly activated during the washing proce-
dures.
pFibrin (> 5 lg mL1) was able to induce platelet
aggregation (Figure S2); mFab-F prolonged its lag-time
but did not reduce maximum aggregation, whereas 45-
lM Eptifibatide (anti-aIIbb3) abrogated it. This suggests
that platelet aggregation through pFibrin in suspension
doesn’t require GPVI-dimer. Fibrinogen, D-fragment
and D-dimer (5–20 lg mL1) did not induce platelet
aggregation (Fig. 5A-i). However, D-dimer concentra-
tion-dependently inhibited Horm-induced aggregation of
washed platelets (Fig. 5A-ii). In platelets pre-incubated
with 100 lg mL1 Horm, lower D-dimer concentrations
did not affect mFab-F inhibition of Horm-induced
aggregation, but high D-dimer concentration relieves the
inhibition, suggesting that D-dimer may bind at a
Fig. 1. Interaction of GPVI-Fc2 and GPVIex with immobilized fibrinogen derivatives. The following abbreviations were used in the graphs:
collagen type III (Col); D-fragment (D-frag); D-dimer (D-D); E-fragment (E-frag); fibrinogen-Sigma (Fbg-Sig), pFibrin-Sigma (pFn-Sig), mFib-
rin-Sigma (mFn-Sig); fibrinogen-1 (Fbg-1), pFibrin-1 (pFn-1), mFibrin-1 (mFn-1); fibrinogen-3 (Fbg-3), pFibrin-3 (pFn-3), mFibrin-3 (mFn-3);
fibrinogen peak 1 (Fbg Pk1); fibronectin (Fibro); vitronectin (Vitro); BSA (bovine serum albumin). Binding of GPVI-Fc2 (recombinant GPVI-
dimer), GPVIex (recombinant GPVI monomer), DDR2-Fc2, human Fc and human IgG to immobilized fibrinogen derivatives was measured by
ELISA (enzyme-linked immunosorbent assay) as detailed in the Methods. Collagen type III (Col) was used as a positive control. The numbers
in parentheses indicate the concentrations of substrate used to coat the ELISA plate wells in lg mL1 in PBS. Non-specific binding was deter-
mined with BSA alone, which was subtracted from the total binding to obtain specific binding. (A) Fibrinogen-Sigma, fibrinogen-1, fibrinogen-
3 and fibrinogen peak 1 are the fibrinogens described in Figure S1 and the corresponding polymerized (pFibrin) and monomeric fibrins (mFib-
rin) produced from thrombin +/ GPRP addition, respectively. Fluorescence values shown are the mean  SEM, from five different experi-
ments, with duplicate repeats in each. GPVI-Fc2 (50 lg mL
1 shown) shows high levels of binding to D-fragment, D-dimer and col III. In
contrast, there is only very low binding to fibrinogen, mFibrin and pFibrin and no binding to E-fragment, fibrinogen peak 1, fibronectin or vit-
ronectin. (B) GPVIex (50 lg mL
1) showed no binding to immobilized fibrinogen-Sigma, fibrinogen-1, fibrinogen-3, D-fragment or D-dimer
with some binding to collagen III, suggesting that the GPVI monomer is unable to recognize the D-domain. (C) No increase in binding to
GPVI-Fc2 is seen with fibrinogen-3 (Fbg-3) or pFibrin-3 and mFibrin-3 produced from it, at higher concentrations (Fbg-3; 10–200 lg mL
1),
whereas collagen III, D-fragment and D-dimer bind at 10 lg mL1. (D) Human Fc shows no binding to the fibrinogen derivatives and no
binding to col III. Immobilized DDR2-Fc2 (20 lg/mL) binds collagen as expected, but neither DDR2-Fc2, human Fc (20 lg/mL) nor human
IgG (25 lg mL1) bind to fibrinogen, whereas matched concentrations of GPVI-Fc2 bind well to D-fragment, D-dimer and collagen. (E)
Kinetic analyses of the binding of GPVI-Fc2 to D-fragment and D-dimer to determine Kd (dissociation constant) values. GPVI-Fc2 exhibits sat-
urable binding to both D-fragment and D-dimer (coated at two different concentrations), with Kd values (data fit to a non-linear regression,
one-site model) shown in the inset. The Kd values for D-fragment and D-dimer are similar and they are comparable to the Kd value for col III.
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separate but nearby site, perhaps producing a conforma-
tional change that may reduce the affinity of mFab
(Fig. 5A-iii).
Therefore, fibrinogen derivatives in solution are not
able to bind to platelet GPVI-dimer or GPVI-Fc2.
Although D-dimer appears to bind to GPVI-dimer in
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suspension, it does not cause aggregation, and indeed
inhibited it, an important physiological barrier to prevent
platelets from spontaneous aggregation through GPVI-
dimer.
Platelet adhesion to fibrinogen substrates under static
conditions and effect of inhibiting antibodies
Under static conditions, washed platelets adhere to fib-
rinogen, D-fragment, pFibrin, mFibrin and D-dimer (Fig.
3), but not to E-fragment (data not shown in Fig. 3).
mFab-F mildly but significantly inhibited platelet adhe-
sion to D-fragment, mFibrin, pFibrin and col III,
whereas hFab (human Fab) had no effect. Hip8 dramati-
cally decreased platelet adhesion on fibrinogen, D-frag-
ment, D-dimer, mFibrin and pFibrin. mFab-F + Hip8
further decreased platelet adhesion on D-fragment, D-
dimer, mFibrin and pFibrin. Thus, static adhesion to fib-
rinogen substrates is mainly aIIbb3-dependent, with a
small contribution by GPVI-dimer. In contrast, static
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Fig. 3. Platelet adhesion to immobilized fibrinogen substrates under static conditions and effect of antibodies against GPVI-dimer and integrin
aIIbb3. Adhesion of washed platelets pretreated with human Fab (control, 200 lg mL1), mFab-F (200 lg mL1), Hip8 (anti-GPIIba, inhibi-
tory, 10 lg mL1), or a combination of mFab-F (200 lg mL1) and Hip8 (10 lg mL1), was determined as previously described; in this assay,
the adhered platelets are lysed and their content of alkaline phosphatase measured in an assay using the chromogenic substrate p-nitrophenyl
phosphate, which is hydrolyzed by this enzyme to p-nitrophenol, which is detectable at 405-nm absorbance. Data shown are the mean  SD of
three separate experiments, each data point run in duplicate, using platelets from three different healthy control individuals. Data were ana-
lyzed by the paired t-test, with significances shown on the figure: control (human Fab) vs. mFab-F, Hip8 or mFab8 + Hip8 (*P < 0.05,
**P < 0.01,***P < 0.001); mFab vs. Hip8 (**P < 0.01, ***P < 0.001); Hip8 vs. Hip8 + m-Fab-F (*P < 0.05,**P < 0.01); ns = not significant.
Platelets adhere to fibrinogen, pFibrin (polymerized fibrin made from Fib-3), mFibrin (monomeric fibrin made from Fib-3), D-fragment,
D-dimer and collagen type III (col III), the positive control. Platelets do not adhere to E-fragment, so the following discussion of antibody
effects only refers to the substrates supporting platelet adhesion. mFab-F mildly but significantly decreased platelet binding to D-fragment,
m-fibrin, p-fibrin and collagen. Hip8 markedly decreases platelet adhesion to all fibrinogen substrates, but has no effect on platelet adhesion to
collagen, which is mainly supported by integrin a2b1. Adding mFab-F and Hip8 together further diminishes platelet adhesion to all immobi-
lized fibrinogen substrates, suggesting that integrin aIIbb3 plays the predominant role but GPVI-dimer makes a significant contribution.
Fig. 2. Collagenous substrates compete with GPVI-dimer binding to immobilized D-fragment and D-dimer, but fibrinogen substrates in solu-
tion do not displace binding of GPVI-dimer to immobilized collagen substrates. (A) Collagenous substrates inhibit the binding of GPVI-Fc2 to
D-fragment and D-dimer. D-fragment or D-dimer (10 lg mL1) was immobilized to ELISA wells and left overnight at 4 °C. GPVI-Fc2
(20 lg mL1) was incubated with increasing concentrations of collagenous substrate (0–20 lg mL1) and ELISA performed as described in the
Methods. The following collagenous substrates were tested: collagen type III (col III, non-fibrous), Horm collagen (fibrous), CRP-XL and
GPP10-XL. (A i) CRP-XL inhibited GPVI-Fc2 binding to D-fragment, abrogating it at ≥ 0.05 lg mL
1 and col III and Horm, at ≥ 0.5
lg mL1. GPP10-XL, which does not bind to GPVI-Fc2, did not affect the binding. (A ii) GPVI-Fc2 binding to D-dimer was similarly inhib-
ited by col III, Horm and CRP-XL, although slightly higher concentrations of col III and Horm were needed to obtain the same degree of
inhibition. (B) Col III, Horm and CRP-XL (10 lg mL1) were immobilized to ELISA wells and left overnight at 4 °C. D-fragment, D-dimer,
E-fragment, fibrinogen (Fib-3) and its respective pFibrin (0–20 lg mL1) incubated with GPVI-Fc2 (20 lg mL
1) cannot inhibit GPVI-Fc2
binding to col III (B i), HORM (B ii), or CRP-XL (B iii), suggesting that D-domain in solution does not have sufficient affinity for GPVI-Fc2.
Data are presented as the mean  SEM obtained from three separate experiments with each data point as a duplicate.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
GPVI-dimer recognizes the fibrin(ogen) D-domain 7
Human Fab
Fi
br
in
og
en
D
-fr
a
gm
en
t
D
-d
im
er
m
Fi
br
in
pF
ib
rin
H
or
m
 
co
lla
ge
n
mFab-F Dasatinib GPVI
pFibrin
Merge
Light transmission
20 µm
10 µm
20 µm
P-selectinA B
Fig. 4. Confocal images of washed platelets adhered to fibrinogen derivatives and Horm collagen and the effect of inhibitors. Washed platelets
suspended in HT buffer were pretreated with human Fab (control, 200 lg mL1), inhibitory anti-GPVI-dimer mFab-F (200 lg mL1) or the
Src inhibitor Dasatinib (50 nM) for 10 min and then were allowed to adhere to fibrinogen, fibrinogen derivative or Horm collagen immobilized
on MatTek glass dishes, followed by fixation and staining with fluorescently labelled antibody (as described in the Methods). (A) Images show
platelets stained with Alexa-fluor 488–1G5 (green; pan GPVI) and Alexa-fluor 647–anti-P-selectin (red) to measure platelet activation. Images
were obtained with a 60x oil immersion objective on an Olympus confocal microscope. As shown in (A) (left-most column of images), platelets
spread well on fibrinogen, D-fragment, mFibrin and Horm collagen, with evident surface expression of P-selectin. Platelet aggregate formation
was seen on pFibrin, whereas platelets spread but did not appear aggregated on mFibrin. Horm collagen supported aggregate formation, with
the characteristic binding of GPVI along the Horm fibers [31]. In contrast, platelets did not spread well on D-dimer, with only some platelets
showing P-selectin expression. Treatment with mFab-F (A, middle column of images) prevented platelet spreading on fibrinogen, D-fragment
and Horm collagen, and decreased the extent of spreading, with evident filopodia observed, on mFibrin and pFibrin, whereas there was little
change in the less-spread platelets on D-dimer. mFab-F prevented aggregate formation on both pFibrin and Horm collagen, consistent with
inhibition of activation through GPVI. Dasatinib (A, right-most column of images) shows effects similar to those of mFab-F. (B) In these
experiments, the immobilized pFibrin or mFibrin (data not shown) was stained with anti-fibrin/Alexa-fluor 547–anti-mouse IgG (blue) after the
surface was blocked with 1% bovine serum albumin; the dishes were then thoroughly washed and used for the platelet adhesion experiments,
which were performed as shown in (A). pFibrin (blue) is clearly evident, whereas there was no staining of the immobilized mFibrin (data not
shown). P-selectin (red) expression and aggregate formation is evident on the surface of the adhered platelets.
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adhesion on collagen mainly depends on a2b1, with a les-
ser contribution by GPVI-dimers, under the present non-
cation-depleted conditions [4].
Platelet spreading on immobilized fibrinogen substrates
requires GPVI-dimer
Confocal images (Fig. 4A) of platelets labeled for pan-
GPVI (Alexa-fluor 488–1G5, green) and P-selectin
(Alexa-fluor 647–anti-CD 62p, red) indicate that platelets
spread well, with P-selectin expression, on fibrinogen,
D-fragment, mFibrin and pFibrin, which shows clear
aggregate formation. Little spreading occurred on
D-dimer. mFab-F and Dasatinib (Src-kinase inhibitor)
cause similar inhibition of platelet spreading on fibrino-
gen and D-fragment, and although platelets still spread
on pFibrin, aggregate formation is obviously reduced.
As expected, platelets bind through GPVI on Horm
fibers, with surface P-selectin expression, as reported
before [31]. Figure 4(B) shows a representative image of
immobilized pFibrin fibers, pre-stained as described in
the Methods, before platelets were added, with adhered
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Fig. 5. Binding of GPVI-dimer to D-fragment, D-dimer, fibrinogen and fibrin in solution and effect of mFab-F on static adhesion to
D-domain. (A) Aggregometry was performed with washed platelets (2.5 9 108) either untreated or incubated for 5 min with mFab-F
(100 lg mL1)). At 3 min, D-fragment, D-dimer or fibrinogen (parentheses indicate concentrations in lg mL1) was added to the platelets
(A i–iii). D-fragment, D-dimer or fibrinogen do not cause aggregation up to the maximum concentration (20 lg mL1). If no aggregation
occurred by 8 min, Horm was added to induce platelet aggregation, verifying that the platelets were active. D-dimer inhibits Horm-induced
aggregation (A i) in a concentration-dependent manner (A ii). (A iii) Washed platelets were pre-incubated with 100 lg mL1 of mFab-F for
5 min. D-dimer (5–20 lg mL1) was added at 3 min and Horm (3 lg mL1) at 8 min. Horm-induced aggregation is inhibited when mFab-F is
present, although at higher concentrations of D-dimer (20 lg mL1) some aggregation occurs. The images are representative of results from
three experiments. (B) ELISA plates were coated with col III, D-fragment or D-dimer (25 lg mL1) and left overnight at 4 °C. GPVI-Fc2
(25 lg mL1) was incubated with either 100 lg mL1 human Fab (hFab), as a control, or 100 lg mL1 mFab-F for 1 h at room temperature
and reacted with the coated substrates. Bound GPVI-Fc2 was detected as detailed in the Methods. Results, presented as the mean  SEM, con-
firm that mFab-F significantly reduces GPVI-Fc2 binding to D-fragment, D-dimer (P < 0.01) and collagen (P < 0.05). (C) Flow cytometry
assessment of fibrinogen and D-dimer binding in normal and GT platelets, with isotype control (IgG1). Washed platelets from the GT patient
and a normal donor were incubated with 20 lg mL1 of fibrinogen or D-dimer for 30 min; samples were diluted 10-fold with CBS, pelleted by
centrifugation and resuspended in HT; then each sample was incubated with anti-human fibrinogen for 10 min, followed by addition of an
excess of Alexa fluor-488–anti-mouse Fab. Samples were measured in an Accuri C6 flow cytometer. The normal platelets show low levels of fib-
rinogen and D-dimer binding, but the GT platelets show neither, suggesting that integrin aIIbb3 is mainly responsible for binding to fibrinogen
and D-dimer.
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Fig. 6. Adhesion of platelets in whole blood to fibrinogen substrates and collagen under flow conditions. The following abbreviations were used
in the graphs (B–E): D-fragment (D-frag), D-dimer (D-D), fibrinogen (Fbg), pFibrin (pFn), mFibrin (mFn) and collagen type III (col). Glass
coverslips were coated with fibrinogen (Fbg-3), pFibrin and mFibrin (produced from Fbg-3), D-fragment, D-dimer and collagen type III at
10 lg mL1 in PBS and left overnight at 4 °C. Blood was anticoagulated with 36 lL D-phenylalanyl-prolyl-arginyl chloromethyl ketone
(PPACK) and topped up at 1 : 1000 ratio every hour. Platelets in whole blood were fluorescently labelled with 1:4500 DiOC6 (3,30-dihexyloxa-
carbocyanine iodide). After 1-min perfusion of flow buffer (136 mM NaCl, 2.7 mM KCl, 5 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid, 10 mM glucose, 2 mM MgCl2, 2 mM CaCl2, pH 7.4), whole blood was perfused over the coverslips at a shear rate of 350 s
1. Z-stack
images were used to calculate surface coverage (SA) of adhered platelets and mean thrombus height (MTH) in panels B–E. (A) Fluorescently
labelled whole blood was left untreated (control) or treated with one of the following: human Fab (hFab, 100 lg mL1), mFab-F (GPVI-dimer
specific, inhibitory; 100 lg mL1), Eptifibatide (aIIbb3 inhibitor, 45 lM; Tocris Bioscience, UK), Gi9 (anti-a2b1, inhibitory; GeneTex, USA).
The images in Panel A are representative of six flow experiments performed with blood from different donors. Statistical significance between
control and antibody inhibition (B + C) or human Fab and mFab-F inhibition (D + E) was calculated using paired t-tests (*P < 0.05,
**P < 0.01 ***P < 0.001). (B + C) Inhibition of aIIbb3 abrogated SA and MTH to all surfaces. mFab-F reduced platelet adhesion (SA) to all
five fibrinogen derivatives (D-fragment, **P < 0.01; all others, *P < 0.05) and col III (*P < 0.05). mFab-F also significantly suppressed MTH
on D-fragment, mFibrin and col type III (**P < 0.01) and reduced it on D-dimer, fibrinogen and pFibrin compared with the control. This sug-
gests that GPVI-dimer is able to facilitate platelet adhesion and thrombus growth on fibrinogen derivatives, through the D-domain. (C + D)
The inhibition of GPVI-dimer with mFab-F compared with the effect of human Fab and anti-a2b1 Gi9 under the same conditions. a2b1 had
little to no effect on adhesion to fibrinogen derivatives, and as expected caused some reduction of aggregate formation (MTH) on collagen.
mFab-F significantly reduced SA and MTH compared with human Fab on all tested substrates, except SA on D-fragment and D-dimer, which
nevertheless tended towards significance (P = 0.07 and P = 0.08, respectively).
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platelets showing pan-GPVI and surface P-selectin
expression.
Both GPVI-dimer and integrin aIIbb3 contribute to platelet
adhesion and thrombus formation on fibrinogen derivatives
under flow conditions
Human blood from a healthy donor was perfused over
immobilized fibrinogen derivatives or col III (control) at
350 s1 (Fig. 6) and 1000-s1 (Figure S3). Thrombus
formation is apparent on all control images (left column,
Fig. 6A). Addition of mFab-F (middle column of images,
Fig. 6A) decreases both platelet adhesion (SA) (Fig. 6B)
and mean thrombus height (MTH) (Fig. 6C) on all tested
surfaces. Eptifibatide abrogated platelet adhesion on all
four fibrinogen derivatives (right column, Fig. 6A).
Inhibition of a2b1 by mAb Gi9 (10 lg mL1) only
mildly inhibited adhesion on collagen, but not the fibrino-
gen substrates. Compared with hFab (100 lg mL1),
GPVI-dimer inhibition resulted in reduced SA and MTH
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Fig. 7. Static adhesion of platelets from an individual with Glanzmann thrombasthenia (GT) on immobilized fibrinogen substrates. (A) Flow
cytometry analysis verified that the GT platelets contain no integrin aIIbb3, but had normal levels of GPVI. (B) In these experiments, the
ELISA wells were coated by adding a 100-lg mL1 solution of each substrate. The GT platelets did not adhere to fibrinogen or D-fragment,
but retained the ability to adhere to pFibrin and D-dimer, although this was markedly reduced. mFab-F markedly reduced the adhesion on
pFibrin, suggesting that GPVI-dimer may be involved in this interaction. (C) Confocal images of normal platelet and GT platelets adhered to
immobilized pFibrin. Both normal and GT platelets were prelabelled with Alexa fluor 488-conjugated 204-11 Fab and allowed to adhere on
pFibrin-coated MatTek dishes, for 30 min at 37 °C. The platelets were then fixed and stained with Alexa fluor 647-conjugated antibody specific
for integrin aIIbb3 (normal platelets) or GPIb (GT platelets), as described in the text, before imaging. The GT platelets retain the ability to
adhere to pFibrin, although they do not spread; close inspection of the transmitted light images shows that the GT platelets adhere on or close
to the fibers of pFibrin.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
GPVI-dimer recognizes the fibrin(ogen) D-domain 11
on all fibrinogen derivatives (Fig. 6D and E). All differ-
ences were statistically significant apart from mean SA on
D-fragment and D-dimer, which was close to reaching sig-
nificance (P = 0.07 and P = 0.08, respectively). This con-
firms that GPVI-dimer contributes to platelet adhesion and
thrombus formation on immobilized fibrinogen and fibrin
surfaces, although the effect of aIIbb3 is greater.
Assessing the role of GPVI-dimer in platelets from a patient
with Glanzmann’s thrombasthenia (GT)
Because platelets contain far fewer GPVI-dimers than
integrin aIIbb3, which may mask the subtler effects of
GPVI-dimer, we examined static adhesion and flow adhe-
sion using blood from a GT patient, whose platelets were
confirmed to have no aIIbb3 but a normal GPVI level
(Fig. 7A).
Static adhesion of GT platelets: Washed GT platelets
showed essentially no adhesion on fibrinogen or D-frag-
ment, but retained a low level of adhesion on pFibrin
and D-dimer (Fig. 7B). mFab-F (100 lg mL1) further
diminished the adhesion to pFibrin, suggesting that this
low level of interaction involved GPVI-dimer.
Confocal imaging showed that some GT platelets pre-
labelled with Alexa-fluor 488-conjugated 204-11-Fab
(green) and post-labelled with Alexa-fluor 647-conjugated
anti-GPIb (red) (Fig. 7C) adhered to pFibrin fibers
(Fig. 7C, transmitted light image), but did not spread/ag-
gregate like the normal platelets (post-labelled with
Alexa-fluor 647-conjugated anti-aIIbb3).
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Fig. 8. Analysis of Glanzmann thrombasthenia (GT) platelets under flow conditions. Blood was obtained from an individual with GT, whose
platelets lack integrin aIIbb3. (A) Labelled whole blood was then perfused over surfaces of D-fragment, D-dimer, fibrinogen and pFibrin (slides
were coated with 100 lg mL1 of substrate in PBS, overnight at 4 °C). Whole blood was obtained from a healthy volunteer for control mea-
surements. Thrombasthenic blood was perfused with or without the addition of mFab-F (100 lg mL1) at 350 s1. GT platelets retain some
ability to adhere on all four surfaces, albeit at dramatically reduced levels compared with normal platelets and there is no aggregate formation.
mFab-F further reduced the level of adherent GT platelets. Z-stack images were used to calculate SA (B) and MTH (C). For the GT platelets,
inhibition of GPVI-dimers by mFab-F causes a further reduction of platelet adherence and activation on D-fragment and D-dimer.
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Under flow conditions, adhesion of GT platelets to
D-fragment, D-dimer, fibrinogen and pFibrin was dra-
matically reduced, but platelet adhesion was still evident
(Fig. 8A). Quantitation of SA (Fig. 8B) showed that GT
platelets retain some ability to adhere to fibrinogen, pFib-
rin, D-fragment and D-dimer. Their SA on D-fragment
and D-dimer was reduced by mFab-F, suggesting GPVI-
dimer involvement in this adhesion. MTH for the GT
platelets (Fig. 8C) was very low, indicating little platelet
activation had occurred. This suggests that the absence of
aIIbb3 does not abolish the interaction between GPVI
and fibrinogen substrates, although it appears that its
absence impairs the ability of platelets to activate on fib-
rinogen and fibrin.
Discussion
GPVI-dimer, constitutively present in resting platelets [4],
by virtue of its high affinity for collagen, is the functional
form of this receptor that initiates signaling leading to
thrombogenesis [27]. Recent work has identified GPVI as
a fibrin receptor. Mammadova-Bach et al. [24] first
showed that GPVI promoted thrombin generation
through fibrinogen and fibrin-dependent mechanisms and
that Fab 9O12 (inhibitory antibody against pan GPVI)
[34] reduced platelet adhesion to fibrin and platelet
recruitment to formed fibrin-rich thrombi [24]. Subse-
quently, Alshehri et al. concluded that fibrin stimulates
tyrosine kinase phosphorylation and platelet spreading
through GPVI, independent of aIIbb3 [25], and Onselaer
et al. recently reported that GPVI-monomer binds to fib-
rin [26].
The present study presents the novel finding that
GPVI-dimer, not the monomer, binds to immobilized fib-
rinogen and fibrin through their D-domains. GPVI-dimer
binds to the D-domain with high affinity, exhibiting Kd
values similar to that for collagen (Fig. 1A, E). We found
that GPVI-monomer bound to none of the fibrinogen
derivatives (Fig. 1B), confirming a specific interaction
between GPVI-dimer and the D-domain. Neither recom-
binant nor platelet GPVI-dimer binds E-fragment. Inter-
estingly, the ability of collagenous substrates to inhibit
GPVI-dimer binding to D-fragment and D-dimer
(Fig 2A), as well as the ability of soluble D-dimer to inhi-
bit collagen-induced platelet aggregation (Fig 5A-ii), sug-
gests that the collagen and D-domain binding sites on
GPVI-dimer are proximate.
The collagen-binding properties of the GPVI-ectodomain
used by the Watson group (Alsheri et al. [25]) initially have
not been characterized, so we are unable to compare it with
our GPVIex. Subsequently, they (Onselaer et al. [26]) used
recombinant GPVI proteins and concluded that GPVI-
monomer selectively binds to fibrin. We found the opposite
to be true: only GPVI-dimer binds to the D-domain com-
mon to fibrinogen and its derivatives, consistent with the
specific binding of the recombinant GPVI-Fc to fibrin
reported by Mammadova-Bach et al. [24]. These discrepan-
cies would come from the difference between our GPVI
recombinant proteins and those used by the Watson group:
their recombinant proteins do not include the highly glyco-
sylated, sialic-acid-rich stem portion of GPVI and the lack
of such strong anionic charges would influence the binding
of their recombinant GPVI to fibrin. To obviate the poten-
tial problem caused by the lack of carbohydrate in their
constructs, they showed that Revacept, a dimeric GPVI-Fc-
fusion protein, also did not bind fibrin. However, Revacept
has a different structure from platelet GPVI-dimer and our
recombinant dimer because a flexible linker sequence has
been inserted between the GPVI-extracellular domain and
the Fc portion [35]. This may make its conformation differ-
ent from that of physiological GPVI-dimer and thereby
change its ability to bind to fibrin. It must be highlighted
that our antibodies 204-11 Fab and mFab-F, designed
against our GPVI-Fc2, are able to recognize both the con-
stitutive dimers present on resting platelets and those on
activated platelets and mFab-F inhibits Horm-induced
aggregation, supporting that our GPVI-Fc2 is similar to
physiological platelet GPVI-dimers.
A key finding from our work is that the immobilized
nature of the fibrinogen substrates is important for plate-
let activation through GPVI-dimer. Fibrinogen subdo-
mains in solution with GPVI-dimer cannot inhibit its
binding to collagen (Fig. 2B) and GT platelets lacking
aIIbb3 fail to bind fibrinogen and D-dimer in solution
(Fig. 5C). Aggregometry confirms that D-fragment, D-
dimer and fibrinogen in solution do not cause platelet
aggregation (Fig. 5A-i), and pFibrin suspension induces
platelet aggregation independent of GPVI-dimer, presum-
ably via aIIbb3, as mFab-F increased the lag-time, but
did not affect the level of maximum aggregation (Fig-
ure S2). Together, these results suggest that GPVI-dimer
cannot bind to fibrinogen or its subdomains to cause acti-
vation unless they are immobilized. This is crucial as pla-
telet aggregation through binding to soluble fibrinogen
does not occur in the circulation under normal condi-
tions, unless initial platelet activation has occurred, con-
verting resting aIIbb3 to a high-affinity state [36].
Although the fibrinogen and its subdomains in solution
cannot activate platelets, D-dimer, which is found in plasma
at high concentrations under pathological conditions as a
fibrinolytic product, is inhibitory towards platelet activation
through GPVI. Lee et al. [37] reported the ability of
soluble, crosslinked fibrin, which contains the D-dimer moi-
ety, to inhibit platelet activation through GPVI-signaling
and we and Onselaer et al. [26] both found that D-dimer
inhibits collagen-induced platelet aggregation.
GPVI-dimer contributes significantly to static platelet
adhesion, independently of aIIbb3, on immobilized D-
fragment, pFibrin and mFibrin (Fig. 3). Furthermore,
mFab-F inhibition of GPVI-Fc2 leads to a significant
reduction in its binding to D-fragment, D-dimer and col
III in ELISA (Fig. 5B). GPVI-dimer not only contributes
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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to adhesion but also to spreading on fibrinogen, D-frag-
ment, mFibrin, and pFibrin, and aggregate formation on
pFibrin (Fig. 4).
Platelet adhesion to fibrinogen substrates under flow is
more complex than measuring direct binding using ELISA,
because it involves a dominant role for aIIbb3 at lower
(350 s1) and higher (1000 s1) shear, as demonstrated by
the abrogation of thrombus formation in the presence of
Eptifibatide (Fig. 6, Figure S3). GPVI-dimer, however,
appears to play its most significant role at low shear,
because mFab-F significantly decreases SA on all tested
substrates and MTH is significantly reduced on D-frag-
ment, mFibrin and collagen (Fig. 6, Table S1). At
1000 s1, GPVI inhibition appears to produce more vari-
able results, which suggests that GPVI-dimer is less able to
recognize immobilized D-domain at higher shear. This
indicates that aIIbb3 does play a significant role in platelet
interactions with fibrinogen and fibrin in both static
(Fig. 3) and shear (Fig. 6) conditions, whereas GPVI-
dimer has a secondary but requisite role for inducing plate-
let adhesion and thrombus formation.
This could be through convergent tyrosine kinase signal-
ing downstream from GPVI and aIIbb3. For example, the
crosslinking of GPVI induces Src-dependent tyrosine phos-
phorylation of FcRc [2] and, similarly, signaling mediated
by aIIbb3 also includes tyrosine kinases such as Syk and
Src [38,39], with specific blockade reducing the tyrosine
phosphorylation of signaling proteins downstream from
Syk in both the GPVI and aIIbb3 signaling pathways [40].
Dasatinib and mFab-F each exert a similar inhibitory effect
on platelet adhesion, indicating platelet-adhesion-induced
signaling through GPVI-dimer is an important step in pla-
telet spreading and activation on fibrinogen and fibrin
(Fig. 4). This is consistent with Onselaer et al., who show
that fibrin is unable to activate GPVI-deficient human pla-
telets, which is further evidence of shared signaling path-
ways between GPVI and aIIbb3 [26].
Under static conditions, aIIbb3-deficient GT platelets
can adhere to pFibrin, but are not activated (Fig. 7).
Under flow, the GT platelets show drastically reduced
adhesion to D-fragment, D-dimer, fibrinogen and pFibrin,
but residual adherent but non-spread platelets remain
(Fig. 8). mFab-F reduces GT platelet adhesion on all sub-
strates tested, suggesting that GT platelets can bind inde-
pendently through GPVI-dimer, even without functional
aIIbb3, but these adhered GT platelets appear neither
spread nor activated, suggesting that signaling may not
occur without the assistance of aIIbb3. This means that
platelet surface GPVI-dimers may support a weak interac-
tion with immobilized fibrinogen or fibrin, but it is not suf-
ficient to initiate platelet activation. It is more likely that
aIIbb3 and GPVI-dimer have collaborative roles in platelet
activation on fibrinogen and fibrin, especially as platelets
treated with both mFab-F and Hip8 show a further
decrease in adhesion compared with Hip8 alone (Fig. 3).
GPVI antagonism could provide highly specific phar-
macological drugs that prevent thrombus formation in
acute coronary syndrome [41] and ischemic stroke [42].
This study is the first to describe an interaction between
GPVI-dimer and fibrinogen and fibrin. GPVI-dimer binds
to the D-domain and is involved in signaling, leading to
platelet spreading and activation on fibrinogen substrates,
in conjunction with aIIbb3 and independent of collagen
exposure. GPVI-dimer clearly plays a key part in both ini-
tiation and propagation of thrombosis at sites of
atherosclerotic plaque rupture through collagen and
fibrin. However, our findings also intimate a role for
GPVI-dimer in conditions where blood clots form with-
out collagen exposure, including atrial fibrillation and
deep vein thrombosis, making it an even more tantalizing
pharmacological target.
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